Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0000950170-25-034575
Filing Date
2025-03-06
Accepted
2025-03-06 16:01:55
Documents
100
Period of Report
2024-12-31

Document Format Files

Seq Description Document Type Size
1 10-K ctmx-20241231.htm   iXBRL 10-K 3690265
2 EX-23.1 ctmx-ex23_1.htm EX-23.1 7547
3 EX-31.1 ctmx-ex31_1.htm EX-31.1 15032
4 EX-31.2 ctmx-ex31_2.htm EX-31.2 14819
5 EX-32.1 ctmx-ex32_1.htm EX-32.1 12365
6 GRAPHIC img241899024_0.jpg GRAPHIC 83263
7 GRAPHIC img241899024_1.jpg GRAPHIC 75698
8 GRAPHIC img241899024_2.jpg GRAPHIC 138758
  Complete submission text file 0000950170-25-034575.txt   14369550

Data Files

Seq Description Document Type Size
9 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT ctmx-20241231.xsd EX-101.SCH 1848475
103 EXTRACTED XBRL INSTANCE DOCUMENT ctmx-20241231_htm.xml XML 2356515
Mailing Address 151 OYSTER POINT BLVD. SUITE 400 SOUTH SAN FRANCISCO CA 94080
Business Address 151 OYSTER POINT BLVD. SUITE 400 SOUTH SAN FRANCISCO CA 94080 650.515.3185
CytomX Therapeutics, Inc. (Filer) CIK: 0001501989 (see all company filings)

EIN.: 273521219 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K | Act: 34 | File No.: 001-37587 | Film No.: 25715108
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)